nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—Etoposide—sarcoma	0.108	0.174	CbGbCtD
Pomalidomide—CYP1A2—Dacarbazine—sarcoma	0.083	0.134	CbGbCtD
Pomalidomide—CYP3A4—Thiotepa—sarcoma	0.0785	0.127	CbGbCtD
Pomalidomide—ABCB1—Dactinomycin—sarcoma	0.0629	0.101	CbGbCtD
Pomalidomide—ABCB1—Mitoxantrone—sarcoma	0.0563	0.0908	CbGbCtD
Pomalidomide—CYP1A2—Etoposide—sarcoma	0.0406	0.0655	CbGbCtD
Pomalidomide—ABCB1—Vincristine—sarcoma	0.0388	0.0625	CbGbCtD
Pomalidomide—ABCB1—Etoposide—sarcoma	0.0355	0.0573	CbGbCtD
Pomalidomide—CYP3A4—Mitoxantrone—sarcoma	0.0337	0.0544	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—sarcoma	0.0242	0.039	CbGbCtD
Pomalidomide—CYP3A4—Vincristine—sarcoma	0.0232	0.0374	CbGbCtD
Pomalidomide—CYP3A4—Etoposide—sarcoma	0.0213	0.0343	CbGbCtD
Pomalidomide—CYP3A4—Doxorubicin—sarcoma	0.0145	0.0234	CbGbCtD
Pomalidomide—PTGS2—periosteum—sarcoma	0.00474	0.0697	CbGeAlD
Pomalidomide—PTGS2—leg—sarcoma	0.00378	0.0556	CbGeAlD
Pomalidomide—CRBN—myometrium—sarcoma	0.00367	0.054	CbGeAlD
Pomalidomide—CRBN—embryo—sarcoma	0.00353	0.0519	CbGeAlD
Pomalidomide—PTGS2—hindlimb—sarcoma	0.00337	0.0497	CbGeAlD
Pomalidomide—PTGS2—cartilage tissue—sarcoma	0.00332	0.0489	CbGeAlD
Pomalidomide—CRBN—seminal vesicle—sarcoma	0.00331	0.0488	CbGeAlD
Pomalidomide—CRBN—hematopoietic system—sarcoma	0.00315	0.0464	CbGeAlD
Pomalidomide—PTGS2—appendage—sarcoma	0.00289	0.0426	CbGeAlD
Pomalidomide—TNF—lymph node—sarcoma	0.00262	0.0385	CbGeAlD
Pomalidomide—CRBN—cardiac atrium—sarcoma	0.00239	0.0352	CbGeAlD
Pomalidomide—CRBN—uterus—sarcoma	0.00238	0.035	CbGeAlD
Pomalidomide—CRBN—lymphoid tissue—sarcoma	0.00222	0.0326	CbGeAlD
Pomalidomide—CRBN—tendon—sarcoma	0.00208	0.0307	CbGeAlD
Pomalidomide—CRBN—bone marrow—sarcoma	0.00202	0.0297	CbGeAlD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CSF3—sarcoma	0.00175	0.0472	CbGpPWpGaD
Pomalidomide—PTGS2—endothelium—sarcoma	0.00175	0.0257	CbGeAlD
Pomalidomide—CRBN—testis—sarcoma	0.00173	0.0254	CbGeAlD
Pomalidomide—CRBN—liver—sarcoma	0.00163	0.024	CbGeAlD
Pomalidomide—CRBN—lymph node—sarcoma	0.00125	0.0184	CbGeAlD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—TEK—sarcoma	0.00111	0.0297	CbGpPWpGaD
Pomalidomide—CYP1A2—hematopoietic system—sarcoma	0.00104	0.0152	CbGeAlD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—ANGPT2—sarcoma	0.00101	0.0272	CbGpPWpGaD
Pomalidomide—PTGS2—myometrium—sarcoma	0.000999	0.0147	CbGeAlD
Pomalidomide—PTGS2—embryo—sarcoma	0.000961	0.0141	CbGeAlD
Pomalidomide—PTGS2—seminal vesicle—sarcoma	0.000902	0.0133	CbGeAlD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—FOXO1—sarcoma	0.000873	0.0235	CbGpPWpGaD
Pomalidomide—PTGS2—hematopoietic system—sarcoma	0.000858	0.0126	CbGeAlD
Pomalidomide—PTGS2—S1P1 pathway—PLCG1—sarcoma	0.000855	0.023	CbGpPWpGaD
Pomalidomide—PTGS2—connective tissue—sarcoma	0.000826	0.0122	CbGeAlD
Pomalidomide—PTGS2—smooth muscle tissue—sarcoma	0.000755	0.0111	CbGeAlD
Pomalidomide—CYP3A4—hematopoietic system—sarcoma	0.000749	0.011	CbGeAlD
Pomalidomide—PTGS2—skin of body—sarcoma	0.000746	0.011	CbGeAlD
Pomalidomide—TNF—Vitamin B12 Metabolism—HBA1—sarcoma	0.000735	0.0198	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.00069	0.0185	CbGpPWpGaD
Pomalidomide—PTGS2—uterus—sarcoma	0.000648	0.00954	CbGeAlD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—CREB1—sarcoma	0.000633	0.017	CbGpPWpGaD
Pomalidomide—ABCB1—myometrium—sarcoma	0.000618	0.0091	CbGeAlD
Pomalidomide—PTGS2—S1P1 pathway—PDGFRB—sarcoma	0.000606	0.0163	CbGpPWpGaD
Pomalidomide—PTGS2—lymphoid tissue—sarcoma	0.000604	0.00889	CbGeAlD
Pomalidomide—TNF—Folate Metabolism—HBA1—sarcoma	0.000598	0.0161	CbGpPWpGaD
Pomalidomide—ABCB1—embryo—sarcoma	0.000594	0.00875	CbGeAlD
Pomalidomide—PTGS2—tendon—sarcoma	0.000568	0.00836	CbGeAlD
Pomalidomide—ABCB1—seminal vesicle—sarcoma	0.000558	0.00822	CbGeAlD
Pomalidomide—PTGS2—bone marrow—sarcoma	0.00055	0.00809	CbGeAlD
Pomalidomide—CYP1A2—liver—sarcoma	0.000536	0.0079	CbGeAlD
Pomalidomide—ABCB1—hematopoietic system—sarcoma	0.00053	0.00781	CbGeAlD
Pomalidomide—Angiopathy—Etoposide—sarcoma	0.000513	0.00187	CcSEcCtD
Pomalidomide—Mediastinal disorder—Etoposide—sarcoma	0.000509	0.00185	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000509	0.00185	CcSEcCtD
Pomalidomide—Chills—Etoposide—sarcoma	0.000507	0.00185	CcSEcCtD
Pomalidomide—Sepsis—Doxorubicin—sarcoma	0.000506	0.00184	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000505	0.00184	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Epirubicin—sarcoma	0.000505	0.00184	CcSEcCtD
Pomalidomide—Arthralgia—Mitoxantrone—sarcoma	0.000503	0.00183	CcSEcCtD
Pomalidomide—PTGS2—S1P1 pathway—KDR—sarcoma	0.000502	0.0135	CbGpPWpGaD
Pomalidomide—Anxiety—Mitoxantrone—sarcoma	0.000502	0.00183	CcSEcCtD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.000499	0.0134	CbGpPWpGaD
Pomalidomide—Infection—Vincristine—sarcoma	0.000492	0.00179	CcSEcCtD
Pomalidomide—Confusional state—Mitoxantrone—sarcoma	0.000487	0.00177	CcSEcCtD
Pomalidomide—Nervous system disorder—Vincristine—sarcoma	0.000486	0.00177	CcSEcCtD
Pomalidomide—Decreased appetite—Thiotepa—sarcoma	0.000486	0.00177	CcSEcCtD
Pomalidomide—Thrombocytopenia—Vincristine—sarcoma	0.000485	0.00177	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Thiotepa—sarcoma	0.000482	0.00176	CcSEcCtD
Pomalidomide—Decreased appetite—Dactinomycin—sarcoma	0.000482	0.00176	CcSEcCtD
Pomalidomide—Fatigue—Thiotepa—sarcoma	0.000482	0.00175	CcSEcCtD
Pomalidomide—Infection—Mitoxantrone—sarcoma	0.000479	0.00175	CcSEcCtD
Pomalidomide—Hyperhidrosis—Vincristine—sarcoma	0.000479	0.00174	CcSEcCtD
Pomalidomide—Fatigue—Dactinomycin—sarcoma	0.000478	0.00174	CcSEcCtD
Pomalidomide—Pain—Thiotepa—sarcoma	0.000478	0.00174	CcSEcCtD
Pomalidomide—Constipation—Thiotepa—sarcoma	0.000478	0.00174	CcSEcCtD
Pomalidomide—Back pain—Etoposide—sarcoma	0.000476	0.00173	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—HBA1—sarcoma	0.000475	0.0128	CbGpPWpGaD
Pomalidomide—Pain—Dactinomycin—sarcoma	0.000474	0.00173	CcSEcCtD
Pomalidomide—Muscle spasms—Etoposide—sarcoma	0.000473	0.00172	CcSEcCtD
Pomalidomide—Thrombocytopenia—Mitoxantrone—sarcoma	0.000472	0.00172	CcSEcCtD
Pomalidomide—Skin disorder—Mitoxantrone—sarcoma	0.000469	0.00171	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Doxorubicin—sarcoma	0.000467	0.0017	CcSEcCtD
Pomalidomide—Hyperhidrosis—Mitoxantrone—sarcoma	0.000466	0.0017	CcSEcCtD
Pomalidomide—Feeling abnormal—Thiotepa—sarcoma	0.00046	0.00168	CcSEcCtD
Pomalidomide—TNF—Matrix Metalloproteinases—MMP2—sarcoma	0.00046	0.0124	CbGpPWpGaD
Pomalidomide—Hyponatraemia—Epirubicin—sarcoma	0.00046	0.00167	CcSEcCtD
Pomalidomide—Pain in extremity—Epirubicin—sarcoma	0.000458	0.00167	CcSEcCtD
Pomalidomide—Feeling abnormal—Dactinomycin—sarcoma	0.000457	0.00166	CcSEcCtD
Pomalidomide—Anaemia—Etoposide—sarcoma	0.000455	0.00165	CcSEcCtD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—FOXO1—sarcoma	0.000453	0.0122	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Vincristine—sarcoma	0.000451	0.00164	CcSEcCtD
Pomalidomide—Insomnia—Vincristine—sarcoma	0.000448	0.00163	CcSEcCtD
Pomalidomide—PTGS2—liver—sarcoma	0.000444	0.00654	CbGeAlD
Pomalidomide—Vertigo—Etoposide—sarcoma	0.000442	0.00161	CcSEcCtD
Pomalidomide—Body temperature increased—Thiotepa—sarcoma	0.000442	0.00161	CcSEcCtD
Pomalidomide—Leukopenia—Etoposide—sarcoma	0.00044	0.0016	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00044	0.0016	CcSEcCtD
Pomalidomide—Body temperature increased—Dactinomycin—sarcoma	0.000438	0.0016	CcSEcCtD
Pomalidomide—TNF—amb2 Integrin signaling—MMP2—sarcoma	0.000437	0.0117	CbGpPWpGaD
Pomalidomide—Decreased appetite—Vincristine—sarcoma	0.000431	0.00157	CcSEcCtD
Pomalidomide—Dyspnoea—Mitoxantrone—sarcoma	0.00043	0.00157	CcSEcCtD
Pomalidomide—Cough—Etoposide—sarcoma	0.000429	0.00156	CcSEcCtD
Pomalidomide—Blood creatinine increased—Epirubicin—sarcoma	0.000429	0.00156	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Vincristine—sarcoma	0.000428	0.00156	CcSEcCtD
Pomalidomide—Fatigue—Vincristine—sarcoma	0.000427	0.00156	CcSEcCtD
Pomalidomide—Dehydration—Epirubicin—sarcoma	0.000426	0.00155	CcSEcCtD
Pomalidomide—Hyponatraemia—Doxorubicin—sarcoma	0.000425	0.00155	CcSEcCtD
Pomalidomide—Pain—Vincristine—sarcoma	0.000424	0.00154	CcSEcCtD
Pomalidomide—Constipation—Vincristine—sarcoma	0.000424	0.00154	CcSEcCtD
Pomalidomide—Pain in extremity—Doxorubicin—sarcoma	0.000424	0.00154	CcSEcCtD
Pomalidomide—Dry skin—Epirubicin—sarcoma	0.00042	0.00153	CcSEcCtD
Pomalidomide—Decreased appetite—Mitoxantrone—sarcoma	0.000419	0.00153	CcSEcCtD
Pomalidomide—Hypokalaemia—Epirubicin—sarcoma	0.000417	0.00152	CcSEcCtD
Pomalidomide—Fatigue—Mitoxantrone—sarcoma	0.000416	0.00151	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000416	0.00151	CcSEcCtD
Pomalidomide—Breast disorder—Epirubicin—sarcoma	0.000414	0.00151	CcSEcCtD
Pomalidomide—Constipation—Mitoxantrone—sarcoma	0.000413	0.0015	CcSEcCtD
Pomalidomide—Pain—Mitoxantrone—sarcoma	0.000413	0.0015	CcSEcCtD
Pomalidomide—Hypersensitivity—Thiotepa—sarcoma	0.000412	0.0015	CcSEcCtD
Pomalidomide—TNF—IL27-mediated signaling events—IL2—sarcoma	0.000409	0.011	CbGpPWpGaD
Pomalidomide—Nasopharyngitis—Epirubicin—sarcoma	0.000409	0.00149	CcSEcCtD
Pomalidomide—Hypersensitivity—Dactinomycin—sarcoma	0.000409	0.00149	CcSEcCtD
Pomalidomide—Confusional state—Etoposide—sarcoma	0.000405	0.00147	CcSEcCtD
Pomalidomide—Muscular weakness—Epirubicin—sarcoma	0.000404	0.00147	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000404	0.00147	CcSEcCtD
Pomalidomide—Asthenia—Thiotepa—sarcoma	0.000401	0.00146	CcSEcCtD
Pomalidomide—ABCB1—uterus—sarcoma	0.000401	0.0059	CbGeAlD
Pomalidomide—Infection—Etoposide—sarcoma	0.000399	0.00145	CcSEcCtD
Pomalidomide—Asthenia—Dactinomycin—sarcoma	0.000398	0.00145	CcSEcCtD
Pomalidomide—Feeling abnormal—Mitoxantrone—sarcoma	0.000398	0.00145	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL2—sarcoma	0.000397	0.0107	CbGpPWpGaD
Pomalidomide—Blood creatinine increased—Doxorubicin—sarcoma	0.000397	0.00144	CcSEcCtD
Pomalidomide—Pruritus—Thiotepa—sarcoma	0.000395	0.00144	CcSEcCtD
Pomalidomide—Dehydration—Doxorubicin—sarcoma	0.000394	0.00143	CcSEcCtD
Pomalidomide—Thrombocytopenia—Etoposide—sarcoma	0.000393	0.00143	CcSEcCtD
Pomalidomide—Body temperature increased—Vincristine—sarcoma	0.000392	0.00143	CcSEcCtD
Pomalidomide—Skin disorder—Etoposide—sarcoma	0.00039	0.00142	CcSEcCtD
Pomalidomide—CYP3A4—liver—sarcoma	0.000388	0.00572	CbGeAlD
Pomalidomide—Dry skin—Doxorubicin—sarcoma	0.000388	0.00141	CcSEcCtD
Pomalidomide—Hyperhidrosis—Etoposide—sarcoma	0.000388	0.00141	CcSEcCtD
Pomalidomide—Hypokalaemia—Doxorubicin—sarcoma	0.000385	0.0014	CcSEcCtD
Pomalidomide—Breast disorder—Doxorubicin—sarcoma	0.000383	0.00139	CcSEcCtD
Pomalidomide—Diarrhoea—Thiotepa—sarcoma	0.000382	0.00139	CcSEcCtD
Pomalidomide—Body temperature increased—Mitoxantrone—sarcoma	0.000381	0.00139	CcSEcCtD
Pomalidomide—Bronchitis—Epirubicin—sarcoma	0.00038	0.00139	CcSEcCtD
Pomalidomide—Diarrhoea—Dactinomycin—sarcoma	0.000379	0.00138	CcSEcCtD
Pomalidomide—Nasopharyngitis—Doxorubicin—sarcoma	0.000379	0.00138	CcSEcCtD
Pomalidomide—Pancytopenia—Epirubicin—sarcoma	0.000376	0.00137	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000374	0.00136	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—sarcoma	0.000374	0.00136	CcSEcCtD
Pomalidomide—ABCB1—lymphoid tissue—sarcoma	0.000373	0.0055	CbGeAlD
Pomalidomide—Neutropenia—Epirubicin—sarcoma	0.00037	0.00135	CcSEcCtD
Pomalidomide—Dizziness—Thiotepa—sarcoma	0.000369	0.00135	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYOD1—sarcoma	0.000368	0.0099	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD34—sarcoma	0.000368	0.0099	CbGpPWpGaD
Pomalidomide—Upper respiratory tract infection—Epirubicin—sarcoma	0.000368	0.00134	CcSEcCtD
Pomalidomide—Hypersensitivity—Vincristine—sarcoma	0.000365	0.00133	CcSEcCtD
Pomalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	0.000363	0.00977	CbGpPWpGaD
Pomalidomide—Weight increased—Epirubicin—sarcoma	0.00036	0.00131	CcSEcCtD
Pomalidomide—Weight decreased—Epirubicin—sarcoma	0.000358	0.0013	CcSEcCtD
Pomalidomide—Dyspnoea—Etoposide—sarcoma	0.000358	0.0013	CcSEcCtD
Pomalidomide—Hyperglycaemia—Epirubicin—sarcoma	0.000357	0.0013	CcSEcCtD
Pomalidomide—Hypersensitivity—Mitoxantrone—sarcoma	0.000356	0.00129	CcSEcCtD
Pomalidomide—Asthenia—Vincristine—sarcoma	0.000355	0.00129	CcSEcCtD
Pomalidomide—Vomiting—Thiotepa—sarcoma	0.000355	0.00129	CcSEcCtD
Pomalidomide—Pneumonia—Epirubicin—sarcoma	0.000355	0.00129	CcSEcCtD
Pomalidomide—Infestation NOS—Epirubicin—sarcoma	0.000353	0.00128	CcSEcCtD
Pomalidomide—Infestation—Epirubicin—sarcoma	0.000353	0.00128	CcSEcCtD
Pomalidomide—Vomiting—Dactinomycin—sarcoma	0.000353	0.00128	CcSEcCtD
Pomalidomide—Rash—Thiotepa—sarcoma	0.000352	0.00128	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—sarcoma	0.000352	0.00128	CcSEcCtD
Pomalidomide—Dermatitis—Thiotepa—sarcoma	0.000352	0.00128	CcSEcCtD
Pomalidomide—Headache—Thiotepa—sarcoma	0.00035	0.00127	CcSEcCtD
Pomalidomide—Rash—Dactinomycin—sarcoma	0.00035	0.00127	CcSEcCtD
Pomalidomide—Decreased appetite—Etoposide—sarcoma	0.000349	0.00127	CcSEcCtD
Pomalidomide—Pancytopenia—Doxorubicin—sarcoma	0.000348	0.00127	CcSEcCtD
Pomalidomide—Renal failure—Epirubicin—sarcoma	0.000347	0.00126	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Etoposide—sarcoma	0.000347	0.00126	CcSEcCtD
Pomalidomide—Asthenia—Mitoxantrone—sarcoma	0.000346	0.00126	CcSEcCtD
Pomalidomide—Fatigue—Etoposide—sarcoma	0.000346	0.00126	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Epirubicin—sarcoma	0.000346	0.00126	CcSEcCtD
Pomalidomide—Constipation—Etoposide—sarcoma	0.000343	0.00125	CcSEcCtD
Pomalidomide—Pain—Etoposide—sarcoma	0.000343	0.00125	CcSEcCtD
Pomalidomide—Urinary tract infection—Epirubicin—sarcoma	0.000343	0.00125	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—sarcoma	0.000342	0.00125	CcSEcCtD
Pomalidomide—PTGS2—lymph node—sarcoma	0.000341	0.00502	CbGeAlD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—sarcoma	0.00034	0.00124	CcSEcCtD
Pomalidomide—ABCB1—bone marrow—sarcoma	0.00034	0.00501	CbGeAlD
Pomalidomide—Diarrhoea—Vincristine—sarcoma	0.000339	0.00123	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Epirubicin—sarcoma	0.000334	0.00121	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—sarcoma	0.000333	0.00121	CcSEcCtD
Pomalidomide—Epistaxis—Epirubicin—sarcoma	0.000333	0.00121	CcSEcCtD
Pomalidomide—Nausea—Thiotepa—sarcoma	0.000332	0.00121	CcSEcCtD
Pomalidomide—Weight decreased—Doxorubicin—sarcoma	0.000331	0.00121	CcSEcCtD
Pomalidomide—Feeling abnormal—Etoposide—sarcoma	0.000331	0.0012	CcSEcCtD
Pomalidomide—Hyperglycaemia—Doxorubicin—sarcoma	0.00033	0.0012	CcSEcCtD
Pomalidomide—Diarrhoea—Mitoxantrone—sarcoma	0.00033	0.0012	CcSEcCtD
Pomalidomide—Nausea—Dactinomycin—sarcoma	0.000329	0.0012	CcSEcCtD
Pomalidomide—Pneumonia—Doxorubicin—sarcoma	0.000328	0.0012	CcSEcCtD
Pomalidomide—Dizziness—Vincristine—sarcoma	0.000328	0.00119	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—sarcoma	0.000326	0.00119	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—sarcoma	0.000326	0.00119	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—sarcoma	0.000321	0.00117	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Doxorubicin—sarcoma	0.00032	0.00116	CcSEcCtD
Pomalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—sarcoma	0.000317	0.00854	CbGpPWpGaD
Pomalidomide—Body temperature increased—Etoposide—sarcoma	0.000317	0.00116	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—sarcoma	0.000317	0.00116	CcSEcCtD
Pomalidomide—Vomiting—Vincristine—sarcoma	0.000315	0.00115	CcSEcCtD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—IGF1R—sarcoma	0.000314	0.00845	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—IGF1R—sarcoma	0.000314	0.00845	CbGpPWpGaD
Pomalidomide—Urinary tract disorder—Epirubicin—sarcoma	0.000313	0.00114	CcSEcCtD
Pomalidomide—Rash—Vincristine—sarcoma	0.000312	0.00114	CcSEcCtD
Pomalidomide—Dermatitis—Vincristine—sarcoma	0.000312	0.00114	CcSEcCtD
Pomalidomide—Oedema peripheral—Epirubicin—sarcoma	0.000312	0.00114	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—sarcoma	0.000311	0.00113	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—sarcoma	0.00031	0.00113	CcSEcCtD
Pomalidomide—Headache—Vincristine—sarcoma	0.00031	0.00113	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—IL2—sarcoma	0.000309	0.00831	CbGpPWpGaD
Pomalidomide—Hepatobiliary disease—Doxorubicin—sarcoma	0.000309	0.00112	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—PDGFRA—sarcoma	0.000308	0.0083	CbGpPWpGaD
Pomalidomide—Epistaxis—Doxorubicin—sarcoma	0.000308	0.00112	CcSEcCtD
Pomalidomide—Vomiting—Mitoxantrone—sarcoma	0.000307	0.00112	CcSEcCtD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MMP2—sarcoma	0.000306	0.00822	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000305	0.0082	CbGpPWpGaD
Pomalidomide—Rash—Mitoxantrone—sarcoma	0.000304	0.00111	CcSEcCtD
Pomalidomide—Dermatitis—Mitoxantrone—sarcoma	0.000304	0.00111	CcSEcCtD
Pomalidomide—Headache—Mitoxantrone—sarcoma	0.000302	0.0011	CcSEcCtD
Pomalidomide—Hypersensitivity—Etoposide—sarcoma	0.000296	0.00108	CcSEcCtD
Pomalidomide—Nausea—Vincristine—sarcoma	0.000294	0.00107	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—HBA1—sarcoma	0.000294	0.00791	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Epirubicin—sarcoma	0.000294	0.00107	CcSEcCtD
Pomalidomide—ABCB1—testis—sarcoma	0.000291	0.00428	CbGeAlD
Pomalidomide—Urinary tract disorder—Doxorubicin—sarcoma	0.000289	0.00105	CcSEcCtD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000289	0.00778	CbGpPWpGaD
Pomalidomide—Oedema peripheral—Doxorubicin—sarcoma	0.000289	0.00105	CcSEcCtD
Pomalidomide—Asthenia—Etoposide—sarcoma	0.000288	0.00105	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—sarcoma	0.000288	0.00105	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—sarcoma	0.000287	0.00105	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—sarcoma	0.000287	0.00105	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000287	0.00772	CbGpPWpGaD
Pomalidomide—Nausea—Mitoxantrone—sarcoma	0.000287	0.00104	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—sarcoma	0.000285	0.00104	CcSEcCtD
Pomalidomide—Chills—Epirubicin—sarcoma	0.000284	0.00103	CcSEcCtD
Pomalidomide—Pruritus—Etoposide—sarcoma	0.000284	0.00103	CcSEcCtD
Pomalidomide—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000284	0.00763	CbGpPWpGaD
Pomalidomide—Mental disorder—Epirubicin—sarcoma	0.000277	0.00101	CcSEcCtD
Pomalidomide—PTGS2—S1P1 pathway—VEGFA—sarcoma	0.000277	0.00744	CbGpPWpGaD
Pomalidomide—Malnutrition—Epirubicin—sarcoma	0.000276	0.001	CcSEcCtD
Pomalidomide—ABCB1—liver—sarcoma	0.000275	0.00405	CbGeAlD
Pomalidomide—Diarrhoea—Etoposide—sarcoma	0.000275	0.001	CcSEcCtD
Pomalidomide—Cardiac disorder—Doxorubicin—sarcoma	0.000272	0.00099	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—JUN—sarcoma	0.000271	0.0073	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—JUN—sarcoma	0.000271	0.0073	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.00027	0.00726	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—CTNNB1—sarcoma	0.000269	0.00725	CbGpPWpGaD
Pomalidomide—Back pain—Epirubicin—sarcoma	0.000267	0.000971	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—sarcoma	0.000266	0.000968	CcSEcCtD
Pomalidomide—Dizziness—Etoposide—sarcoma	0.000265	0.000966	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—sarcoma	0.000265	0.000965	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—sarcoma	0.000264	0.000961	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—sarcoma	0.000263	0.000957	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.000259	0.00698	CbGpPWpGaD
Pomalidomide—Mental disorder—Doxorubicin—sarcoma	0.000257	0.000935	CcSEcCtD
Pomalidomide—Vomiting—Etoposide—sarcoma	0.000255	0.000929	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—sarcoma	0.000255	0.000929	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—sarcoma	0.000255	0.000928	CcSEcCtD
Pomalidomide—Rash—Etoposide—sarcoma	0.000253	0.000921	CcSEcCtD
Pomalidomide—Dermatitis—Etoposide—sarcoma	0.000253	0.00092	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000252	0.00679	CbGpPWpGaD
Pomalidomide—Headache—Etoposide—sarcoma	0.000251	0.000915	CcSEcCtD
Pomalidomide—Vertigo—Epirubicin—sarcoma	0.000248	0.000902	CcSEcCtD
Pomalidomide—Leukopenia—Epirubicin—sarcoma	0.000247	0.000898	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—sarcoma	0.000247	0.000898	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—sarcoma	0.000245	0.000893	CcSEcCtD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—FOXO1—sarcoma	0.000245	0.00659	CbGpPWpGaD
Pomalidomide—CYP1A2—Estrogen Receptor Pathway—JUN—sarcoma	0.000243	0.00653	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.000243	0.00653	CbGpPWpGaD
Pomalidomide—Cough—Epirubicin—sarcoma	0.000241	0.000876	CcSEcCtD
Pomalidomide—Nausea—Etoposide—sarcoma	0.000238	0.000868	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.000236	0.00635	CbGpPWpGaD
Pomalidomide—Anaemia—Doxorubicin—sarcoma	0.000236	0.000858	CcSEcCtD
Pomalidomide—Arthralgia—Epirubicin—sarcoma	0.000235	0.000854	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—sarcoma	0.000234	0.000851	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—MYOG—sarcoma	0.000234	0.00628	CbGpPWpGaD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000233	0.000849	CcSEcCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—sarcoma	0.000232	0.00624	CbGpPWpGaD
Pomalidomide—Vertigo—Doxorubicin—sarcoma	0.000229	0.000834	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—sarcoma	0.000228	0.000831	CcSEcCtD
Pomalidomide—Confusional state—Epirubicin—sarcoma	0.000227	0.000826	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000226	0.00609	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.000226	0.00609	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—sarcoma	0.000226	0.00607	CbGpPWpGaD
Pomalidomide—Infection—Epirubicin—sarcoma	0.000224	0.000814	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—sarcoma	0.000223	0.00081	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—JUN—sarcoma	0.000222	0.00597	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Epirubicin—sarcoma	0.000221	0.000803	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.00022	0.00593	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—CTNNB1—sarcoma	0.00022	0.00593	CbGpPWpGaD
Pomalidomide—Thrombocytopenia—Epirubicin—sarcoma	0.00022	0.000802	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—sarcoma	0.000219	0.000796	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000218	0.00586	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Epirubicin—sarcoma	0.000218	0.000792	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—sarcoma	0.000217	0.000791	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—sarcoma	0.000216	0.000788	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000216	0.000785	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000215	0.00579	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—FOXO1—sarcoma	0.000211	0.00567	CbGpPWpGaD
Pomalidomide—ABCB1—lymph node—sarcoma	0.000211	0.0031	CbGeAlD
Pomalidomide—Confusional state—Doxorubicin—sarcoma	0.00021	0.000764	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—sarcoma	0.000207	0.000753	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000205	0.000746	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—sarcoma	0.000204	0.000743	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—sarcoma	0.000204	0.000742	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—sarcoma	0.000203	0.000741	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000203	0.00546	CbGpPWpGaD
Pomalidomide—Skin disorder—Doxorubicin—sarcoma	0.000202	0.000736	CcSEcCtD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.000201	0.00541	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Doxorubicin—sarcoma	0.000201	0.000733	CcSEcCtD
Pomalidomide—Dyspnoea—Epirubicin—sarcoma	0.000201	0.00073	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	0.000198	0.00534	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000198	0.00534	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000198	0.00533	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—MYC—sarcoma	0.000196	0.00527	CbGpPWpGaD
Pomalidomide—Decreased appetite—Epirubicin—sarcoma	0.000196	0.000712	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—sarcoma	0.000194	0.00523	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL2—sarcoma	0.000194	0.00523	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Epirubicin—sarcoma	0.000194	0.000707	CcSEcCtD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.000194	0.00522	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—sarcoma	0.000194	0.00522	CbGpPWpGaD
Pomalidomide—Fatigue—Epirubicin—sarcoma	0.000194	0.000706	CcSEcCtD
Pomalidomide—Constipation—Epirubicin—sarcoma	0.000192	0.0007	CcSEcCtD
Pomalidomide—Pain—Epirubicin—sarcoma	0.000192	0.0007	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.00019	0.00069	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—JUN—sarcoma	0.000189	0.00509	CbGpPWpGaD
Pomalidomide—Insomnia—Doxorubicin—sarcoma	0.000188	0.000685	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000187	0.00504	CbGpPWpGaD
Pomalidomide—Dyspnoea—Doxorubicin—sarcoma	0.000186	0.000676	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—sarcoma	0.000185	0.000675	CcSEcCtD
Pomalidomide—Decreased appetite—Doxorubicin—sarcoma	0.000181	0.000659	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—sarcoma	0.00018	0.000654	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—sarcoma	0.000179	0.000653	CcSEcCtD
Pomalidomide—TNF—Apoptosis—MDM2—sarcoma	0.000179	0.00482	CbGpPWpGaD
Pomalidomide—Pain—Doxorubicin—sarcoma	0.000178	0.000648	CcSEcCtD
Pomalidomide—Constipation—Doxorubicin—sarcoma	0.000178	0.000648	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—sarcoma	0.000178	0.000648	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000177	0.00477	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EZR—sarcoma	0.000177	0.00476	CbGpPWpGaD
Pomalidomide—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000175	0.0047	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Doxorubicin—sarcoma	0.000172	0.000625	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—PDGFRB—sarcoma	0.000171	0.00461	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL2—sarcoma	0.000168	0.00453	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Epirubicin—sarcoma	0.000166	0.000603	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—sarcoma	0.000165	0.000599	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—NRAS—sarcoma	0.000163	0.00439	CbGpPWpGaD
Pomalidomide—Asthenia—Epirubicin—sarcoma	0.000161	0.000588	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000159	0.00429	CbGpPWpGaD
Pomalidomide—Pruritus—Epirubicin—sarcoma	0.000159	0.00058	CcSEcCtD
Pomalidomide—TNF—Apoptosis—JUN—sarcoma	0.000156	0.00419	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—sarcoma	0.000155	0.00416	CbGpPWpGaD
Pomalidomide—Diarrhoea—Epirubicin—sarcoma	0.000154	0.00056	CcSEcCtD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	0.000154	0.00413	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Doxorubicin—sarcoma	0.000153	0.000558	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—CREB1—sarcoma	0.000153	0.00411	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000152	0.00409	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.00015	0.00404	CbGpPWpGaD
Pomalidomide—Asthenia—Doxorubicin—sarcoma	0.000149	0.000544	CcSEcCtD
Pomalidomide—Dizziness—Epirubicin—sarcoma	0.000149	0.000542	CcSEcCtD
Pomalidomide—Pruritus—Doxorubicin—sarcoma	0.000147	0.000536	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.000146	0.00393	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—JUN—sarcoma	0.000145	0.0039	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MYOD1—sarcoma	0.000144	0.00388	CbGpPWpGaD
Pomalidomide—Vomiting—Epirubicin—sarcoma	0.000143	0.000521	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—VEGFA—sarcoma	0.000143	0.00385	CbGpPWpGaD
Pomalidomide—Diarrhoea—Doxorubicin—sarcoma	0.000142	0.000519	CcSEcCtD
Pomalidomide—Rash—Epirubicin—sarcoma	0.000142	0.000516	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—sarcoma	0.000142	0.000516	CcSEcCtD
Pomalidomide—Headache—Epirubicin—sarcoma	0.000141	0.000513	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—KIT—sarcoma	0.000141	0.00379	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—KRAS—sarcoma	0.00014	0.00378	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—HRAS—sarcoma	0.00014	0.00377	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.00014	0.00377	CbGpPWpGaD
Pomalidomide—Dizziness—Doxorubicin—sarcoma	0.000138	0.000501	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000136	0.00367	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—PDGFRA—sarcoma	0.000135	0.00364	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000135	0.00362	CbGpPWpGaD
Pomalidomide—Nausea—Epirubicin—sarcoma	0.000134	0.000487	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—JUN—sarcoma	0.000133	0.00359	CbGpPWpGaD
Pomalidomide—Vomiting—Doxorubicin—sarcoma	0.000132	0.000482	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CREB1—sarcoma	0.000132	0.00355	CbGpPWpGaD
Pomalidomide—Rash—Doxorubicin—sarcoma	0.000131	0.000478	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—sarcoma	0.000131	0.000477	CcSEcCtD
Pomalidomide—Headache—Doxorubicin—sarcoma	0.00013	0.000475	CcSEcCtD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.000128	0.00345	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000126	0.00338	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000125	0.00337	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—MYC—sarcoma	0.000125	0.00337	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—NRAS—sarcoma	0.000125	0.00336	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—sarcoma	0.000125	0.00336	CbGpPWpGaD
Pomalidomide—Nausea—Doxorubicin—sarcoma	0.000124	0.00045	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000123	0.0033	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL2—sarcoma	0.000122	0.00328	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HRAS—sarcoma	0.000119	0.00321	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CCND1—sarcoma	0.000119	0.0032	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000116	0.00312	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	0.000115	0.0031	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000112	0.00302	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CTNNB1—sarcoma	0.000109	0.00293	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—sarcoma	0.000108	0.00291	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—KRAS—sarcoma	0.000108	0.0029	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PTPRC—sarcoma	0.000104	0.00281	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—JUN—sarcoma	0.000104	0.0028	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—sarcoma	0.000103	0.00277	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PLCG1—sarcoma	0.000102	0.00275	CbGpPWpGaD
Pomalidomide—CYP1A2—Tryptophan metabolism—MDM2—sarcoma	0.000102	0.00273	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	9.85e-05	0.00265	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CCND1—sarcoma	9.66e-05	0.0026	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MYC—sarcoma	9.55e-05	0.00257	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—JUN—sarcoma	9.5e-05	0.00256	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CTNNB1—sarcoma	9.48e-05	0.00255	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CTNNB1—sarcoma	9.43e-05	0.00254	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	9.41e-05	0.00253	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—EGFR—sarcoma	9.34e-05	0.00251	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	9.3e-05	0.0025	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—HRAS—sarcoma	9.15e-05	0.00246	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	9.08e-05	0.00244	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—JUN—sarcoma	8.95e-05	0.00241	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	8.83e-05	0.00238	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	8.45e-05	0.00227	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—NRAS—sarcoma	8.32e-05	0.00224	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—sarcoma	8.3e-05	0.00223	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	8.29e-05	0.00223	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	8.1e-05	0.00218	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	8.08e-05	0.00217	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	8.02e-05	0.00216	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	7.92e-05	0.00213	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—sarcoma	7.92e-05	0.00213	CbGpPWpGaD
Pomalidomide—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	7.84e-05	0.00211	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—sarcoma	7.84e-05	0.00211	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYC—sarcoma	7.75e-05	0.00208	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—NRAS—sarcoma	7.73e-05	0.00208	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	7.72e-05	0.00208	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	7.62e-05	0.00205	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—sarcoma	7.55e-05	0.00203	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—sarcoma	7.38e-05	0.00198	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCND1—sarcoma	7.36e-05	0.00198	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	7.25e-05	0.00195	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—FOXO1—sarcoma	7.24e-05	0.00195	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	7.24e-05	0.00195	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—sarcoma	7.2e-05	0.00194	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—KRAS—sarcoma	7.16e-05	0.00193	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—sarcoma	7.1e-05	0.00191	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	7.06e-05	0.0019	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—sarcoma	7.04e-05	0.00189	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	6.95e-05	0.00187	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	6.94e-05	0.00187	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	6.94e-05	0.00187	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	6.67e-05	0.0018	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—KRAS—sarcoma	6.65e-05	0.00179	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	6.56e-05	0.00176	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	6.49e-05	0.00175	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	6.35e-05	0.00171	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—sarcoma	6.3e-05	0.0017	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—sarcoma	6.27e-05	0.00169	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	6.09e-05	0.00164	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	6e-05	0.00161	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KDR—sarcoma	5.99e-05	0.00161	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—sarcoma	5.91e-05	0.00159	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—sarcoma	5.9e-05	0.00159	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—sarcoma	5.78e-05	0.00155	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	5.75e-05	0.00155	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	5.58e-05	0.0015	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	5.33e-05	0.00143	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CREB1—sarcoma	5.25e-05	0.00141	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	5.01e-05	0.00135	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	5e-05	0.00134	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	4.96e-05	0.00133	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	4.93e-05	0.00132	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP2—sarcoma	4.89e-05	0.00132	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—sarcoma	4.85e-05	0.0013	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TLE1—sarcoma	4.52e-05	0.00122	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	4.48e-05	0.00121	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	4.37e-05	0.00117	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NPM1—sarcoma	4.08e-05	0.0011	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	4.08e-05	0.0011	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	4.02e-05	0.00108	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	3.93e-05	0.00106	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CTNNB1—sarcoma	3.75e-05	0.00101	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	3.71e-05	0.000998	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	3.55e-05	0.000955	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	3.54e-05	0.000953	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ENO2—sarcoma	3.53e-05	0.00095	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	3.52e-05	0.000946	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—SRC—sarcoma	3.39e-05	0.000912	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—sarcoma	3.3e-05	0.000888	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	3.3e-05	0.000887	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NRAS—sarcoma	3.26e-05	0.000877	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	3.18e-05	0.000855	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	3.09e-05	0.000832	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PLCG1—sarcoma	3e-05	0.000806	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—sarcoma	2.97e-05	0.000799	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ENO2—sarcoma	2.96e-05	0.000796	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HBA1—sarcoma	2.94e-05	0.000791	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CXCR4—sarcoma	2.88e-05	0.000775	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.85e-05	0.000766	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KRAS—sarcoma	2.81e-05	0.000755	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.78e-05	0.000749	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.63e-05	0.000708	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PLCG1—sarcoma	2.51e-05	0.000675	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—sarcoma	2.38e-05	0.000642	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.34e-05	0.000629	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FOXO1—sarcoma	2.13e-05	0.000572	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PDGFRB—sarcoma	2.12e-05	0.000571	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ENO2—sarcoma	2.1e-05	0.000564	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PDGFRA—sarcoma	2.09e-05	0.000562	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HBA1—sarcoma	2.08e-05	0.000561	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PLCG1—sarcoma	1.78e-05	0.000479	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ENO2—sarcoma	1.67e-05	0.00045	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HBA1—sarcoma	1.66e-05	0.000448	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KIT—sarcoma	1.62e-05	0.000436	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CREB1—sarcoma	1.54e-05	0.000415	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PLCG1—sarcoma	1.42e-05	0.000382	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ENO2—sarcoma	1.29e-05	0.000348	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HBA1—sarcoma	1.28e-05	0.000345	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MDM2—sarcoma	1.28e-05	0.000343	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—sarcoma	1.1e-05	0.000296	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLCG1—sarcoma	1.1e-05	0.000295	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SRC—sarcoma	9.95e-06	0.000268	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NRAS—sarcoma	9.58e-06	0.000258	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—sarcoma	8.92e-06	0.00024	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—sarcoma	8.72e-06	0.000235	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KRAS—sarcoma	8.24e-06	0.000222	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—sarcoma	7.01e-06	0.000188	CbGpPWpGaD
